Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Hamilton Thorne Ltd T.HTL

Alternate Symbol(s):  HTLZF

Healthcare Medical Devices
Hamilton Thorne Ltd. is a provider of precision instruments, consumables, software and services to assisted reproductive technologies (ART), research, and cell biology markets. The Company markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, and Embryotech Laboratories brands. It also provides an array of third-party equipment and... see more

TSX:HTL - Post Discussion

Hamilton Thorne Ltd > Hamilton Thorne Reports Record Revenue
View:
Post by Betteryear2 on Apr 07, 2022 8:18am

Hamilton Thorne Reports Record Revenue

BEVERLY, Mass. and TORONTO, April 07, 2022 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the fourth quarter and year-ended December 31, 2021.

Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2021
Comment by dogatcat on Apr 07, 2022 11:16am
Press Release: Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2021 Thursday, April 7, 2022, 8:22 AM ET   Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2021 Revenue of $52.4 million for the year and $15.6 million for the 4th quarter; Adj. EBITDA of $9.8 million for the year and $3.0 ...more  
Hamilton Thorne Ltd
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities